Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperp

Indication
Hyperphagia; Prader-Willi Syndrome

Other upcoming events for AARD

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Open-Label Extension Study to Assess the Safety and Efficacy of ARD-101 in P

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperp — AARD Phase 3 Readout | BioSniper